BeStock  
Stocks › Biotechnology › KRSA

Korsana Biosciences KRSA

US equityMarket cap rank #2789Biotechnology
$37.56 +$2.11 (+5.95%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $37.56 0.00%
Open$35.63
Prev close$35.45
Day range$34.08 – $39.41
Volume265.2K
Market cap$1.71B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$48.27M-119.9% YoY
Net profit-$46.43M-113.7% YoY
Diluted EPS-$3.19+25.4% YoY
Free cash flow-$10.61M
Operating cash flow-$10.61M

Revenue, last 4 quarters

$0.0Sep '25$0.0Dec '25$0.0Jun '26$0.0Sep '26

Net profit, last 4 quarters

$-21.7MSep '25$-13.7MDec '25$-17.4MJun '26$-46.4MSep '26

Diluted EPS by quarter

-4.27Sep '25-2.69Dec '25-3.42Jun '26-3.19Sep '26

Profitability & balance sheet

Return on equity-23.2%
Return on assets-19.7%
Return on invested capital-24.6%
Current ratio10.42
Liabilities / assets15.3%
Cash & investments$456.22M
Total debt$984,000.00
Net cash (debt)$455.24M

Income statement

Line item 2026 Q3 2026 Q2 2025 ANNUAL 2025 Q4 2025 Q3
Research & Development $42.14M $15.51M $32.79M $12.05M $20.48M
-General & Admin Expense $6.14M $2.94M $4.51M $2.92M $1.48M
Selling and Admin Expenses $6.14M $2.94M $4.51M $2.92M $1.48M
Operating Expense $48.27M $18.45M $37.29M $14.97M $21.96M
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Profit -$48.27M -$18.45M -$37.29M -$14.97M -$21.96M
Net Non-Operating Interest Income (Expense) $1.85M $1.09M $1.65M $1.28M $234,000.00
Non-Operating Interest Income $1.85M $1.09M $1.65M $1.28M $234,000.00
Pretax Profit -$46.43M -$17.36M -$35.64M -$13.69M -$21.72M
Net Profit -$46.43M -$17.36M -$35.64M -$13.69M -$21.72M
Net Income to Parent Company -$46.43M -$17.36M -$35.64M -$13.69M -$21.72M
Basic EPS -$3.19 -$3.42 -$7.07 -$2.69 -$4.27
Diluted EPS -$3.19 -$3.42 -$7.07 -$2.69 -$4.27
Net Income to Common Stockholders -$46.43M -$17.36M -$35.64M -$13.69M -$21.72M
Profit from Continuing Operations -$46.43M -$17.36M -$35.64M -$13.69M -$21.72M

Balance sheet

Line item 2026 Q3 2026 Q2 2025 Q4 2025 ANNUAL 2024 ANNUAL
Long Term Debt and Capital Lease Obligation $984,000.00 $917,000.00 – – –
-Long Term Capital Lease Obligation $984,000.00 $917,000.00 – – –
Convertible preferred securities $24.96M $175.54M $175.54M $175.54M $9.96M
Total Equity $391.56M -$63.28M -$33.97M -$33.97M $66,000.00
Stockholders' Equity $391.56M -$63.28M -$33.97M -$33.97M $66,000.00
Capital Stock $0.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
-Common Stock $0.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
Retained Earnings -$113.03M -$66.60M -$35.73M -$35.73M -$88,000.00
Payables $1.61M $462,000.00 $176,000.00 $176,000.00 $68,000.00
Total Current Liabilities $44.20M $12.55M $12.49M $12.49M $78,000.00
Total Liabilities $70.52M $189.43M $188.56M $188.56M $10.04M
Other Non-Current Assets $101,000.00 $3.12M – – –
-Gross PPE $1.33M $1.23M – – –
Net PPE $1.33M $1.23M – – –
Total Non-Current Assets $1.44M $4.35M $0.00 $0.00 $0.00
Other Current Assets $4.43M $639,000.00 $461,000.00 $461,000.00 –
Non-Current Accrued Expenses $376,000.00 $430,000.00 $538,000.00 $538,000.00 $0.00
Total Non-Current Liabilities $26.32M $176.88M $176.08M $176.08M $9.96M
Other Current Liabilities $13.51M $844,000.00 – – –
-Current Capital Lease Obligation $287,000.00 $191,000.00 – – –
Short-Term Debt and Capital Lease Obligation $287,000.00 $191,000.00 – – –
Current Accrued Expenses $28.79M $11.05M $11.94M $11.94M $10,000.00
-Accounts Payable $1.61M $462,000.00 $176,000.00 $176,000.00 $68,000.00
-Cash and Cash Equivalents $456.22M $121.17M $154.14M $154.14M $10.11M
Additional Paid-In Capital $504.59M $3.32M $1.76M $1.76M $153,000.00
Cash and Cash Equivalents & Short-Term Investments $456.22M $121.17M $154.14M $154.14M $10.11M
Total Current Assets $460.65M $121.81M $154.60M $154.60M $10.11M
Total Assets $462.08M $126.16M $154.60M $154.60M $10.11M

Cash flow

Line item 2025 Q4 2025 ANNUAL 2024 ANNUAL
Free Cash Flow -$10.61M -$22.41M $44,000.00
Beginning Cash Balance $163.88M $10.11M $0.00
Net Change in Cash -$9.75M $144.03M $10.11M
Ending Cash Balance $154.14M $154.14M $10.11M
Proceeds from Stock Option Exercised $860,000.00 $860,000.00 $100,000.00
Net Preferred Stock Issuance $0.00 $165.57M $9.96M
Financing Cash Flow $860,000.00 $166.43M $10.06M
-Change in Payables and Accrued Expense $1.95M $12.09M $78,000.00
-Change in Prepaid Assets -$221,000.00 -$461,000.00 $0.00
Change in Working Capital $1.72M $11.63M $78,000.00
Net Income from Continuing Operations -$13.69M -$35.64M -$88,000.00
Net cash flow from continuing operations -$10.61M -$22.41M $44,000.00
Operating Cash Flow -$10.61M -$22.41M $44,000.00
Net Cash Flow from Continuing Financing Activities $860,000.00 $166.43M $10.06M

Discussion

No comments yet — be the first to weigh in on KRSA.

Sign in to join the discussion.

Scroll to Top